NCT07579689Not yet recruitingPhase 4
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
Effect of Gingko Biloba on the Blood Biomarkers in Mild Cognitive Impairment Patients With Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 5 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Hanyang University
- Diseases
- Alzheimer disease
- NCT number
- NCT07579689
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Jun 2026 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.
Other illness
- Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function.
- Known hypersensitivity to Ginkgo biloba extract or any of its components.
- Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives).
- Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.
Lab values
- Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Other
- Refusal to provide informed consent.
- Pregnant women.
Who the study is looking for
- Age 20 years or older
- Clinical Dementia Rating (CDR) score of 0.5
- Patients clinically indicated for treatment with Ginkgo biloba extract
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.